Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 3/20 | 0.42 |
| ▸ | CDK7 | P50613 | 9/20 | 0.39 |
| ▸ | CCNH | P51946 | 9/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 4/20 | 0.37 |
| ▸ | PIP4K2A | P48426 | 3/20 | 0.37 |
| ▸ | PIP4K2B | P78356 | 3/20 | 0.37 |
| ▸ | ITK | Q08881 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.36 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.36 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20211542 | 1.00 | JAK3 (0.42) | JAK3CDK7CCNHLRRK2MAPK8 | |
| SCHEMBL20225395 | 0.92 | CDK7 (0.48) | JAK3CDK7CCNHMAPK8MAPK9 | |
| SCHEMBL18346272 | 0.88 | IRAK4 (0.41) | JAK3LRRK2BTK | |
| SCHEMBL18346293 | 0.85 | IRAK4 (0.38) | JAK3LRRK2 | |
| SCHEMBL20211545 | 0.83 | CDK7 (0.52) | CDK7CCNHMAPK8MAPK9MAPK10 | |
| SCHEMBL20211546 | 0.83 | CDK7 (0.52) | CDK7CCNHMAPK8MAPK9MAPK10 | |
| SCHEMBL18346347 | 0.80 | BTK (0.51) | JAK3EGFRITKBTK | |
| SCHEMBL20211540 | 0.79 | SYK (0.43) | JAK3EGFRITKERBB2ERBB4 | |
| SCHEMBL18346281 | 0.79 | IRAK4 (0.41) | JAK3MAPK8MAPK9EGFRITK | |
| SCHEMBL18346280 | 0.78 | ABL1 (0.41) | JAK3LRRK2MAPK8MAPK9EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10342798-B2 | Fused bicyclic pyrimidine derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180369243-A9 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-12-27 | — | — | US | disclosed |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369243-A9 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | CDK3, CDK14, CDK1 | JAK3 178/4885CDK7 5/4885CCNH 65/4885 |
| US-10342798-B2 | Fused bicyclic pyrimidine derivatives and uses thereof | CDK3, CDK14, CDK1 | JAK3 178/4885CDK7 5/4885CCNH 65/4885 |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | CDK3, CDK14, CDK1 | JAK3 178/4885CDK7 5/4885CCNH 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.